Regulatory and Legal Developments
Compounding pharmacies are suing the to continue producing imitation tirzepatide drugs, including Mounjaro and Zepbound, citing high demand and previous shortages.
has aggressively targeted compounding pharmacies and telehealth companies with cease-and-desist letters, marking a legal escalation against non-name-brand tirzepatide sales.
Patient and Pharmacist Perspectives
Patients and pharmacists express relief as the FDA temporarily allows compounded tirzepatide production while reconsidering its shortage list status, highlighting the medication's accessibility and affordability.
Despite the FDA's recent court filing, patient concerns remain regarding the affordability and availability of name-brand tirzepatide, with some relying on compounded versions for financial relief.